Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 125Gynecologic 7Genitourinary 6Thoracic 4Gastrointestinal 4Other solid neoplasm 2Other hematologic neoplasm 2Lymphoid 2Head & Neck 2Dermatologic 2Sarcoma 1Plasma cell 1Classical hematology 1

Conditions

Melanoma 42Carcinoma, Non-Small-Cell Lung 13Carcinoma, Renal Cell 10Colorectal Neoplasms 9Neoplasm Metastasis 8Ovarian Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Neoplasms 6Breast Neoplasms 6Stomach Neoplasms 5Pancreatic Neoplasms 5Lung Neoplasms 5Head and Neck Neoplasms 4Carcinoma, Transitional Cell 4Carcinoma, Ovarian Epithelial 4Uveal Melanoma 3Esophageal Neoplasms 3Brain Neoplasms 3Triple Negative Breast Neoplasms 2Skin Neoplasms 2Sezary Syndrome 2Sarcoma 2Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Mycosis Fungoides 2Melanoma, Cutaneous Malignant 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2

Interventions

pembrolizumab 28Nivolumab 14Ipilimumab 7Cyclophosphamide 7spartalizumab 6atezolizumab 4Interleukin-2 4fludarabine 3durvalumab 3cemiplimab 3avelumab 3aldesleukin 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Immune Checkpoint Inhibitors 3Docetaxel 3obinutuzumab 2epacadostat 2budigalimab 2bempegaldesleukin 2Pemetrexed 2Paclitaxel 2Leucovorin 2Carboplatin 2CTLA-4 Antigen 2Biopsy 2vocimagene amiretrorepvec 1venetoclax 1utomilumab 1toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Paclitaxel × Dermatologic × Clear all
NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT02983045 2023-03-13

PIVOT-02

Nektar Therapeutics

Phase 1/2 Completed
557 enrolled 22 charts
BreastDermatologicGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡